Development and multinational validation of an algorithmic strategy for high Lp(a) screening

Nature

Center

High Factuality

Development and multinational validation of an algorithmic strategy for high Lp(a) screening

Elevated lipoprotein (a) (Lp(a)) is associated with premature atherosclerotic cardiovascular disease. However, fewer than 0.5% of individuals undergo Lp(a) testing, limiting the evaluation and use of novel targeted therapeutics currently under development. Here we describe the development of a machine learning model for targeted screening for elevated Lp(a) (≥150 nmol l−1) in the UK Biobank (N = 456,815), the largest cohort with protocolized Lp(…